{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T19:01:40Z","timestamp":1761418900511,"version":"build-2065373602"},"reference-count":85,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Chest Medicine"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.ccm.2013.09.005","type":"journal-article","created":{"date-parts":[[2013,11,21]],"date-time":"2013-11-21T16:52:35Z","timestamp":1385052755000},"page":"811-824","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Oral Therapies for Pulmonary Arterial Hypertension"],"prefix":"10.1016","volume":"34","author":[{"given":"Richard","family":"Channick","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iona","family":"Preston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James R.","family":"Klinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccm.2013.09.005_bib1","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/332411a0","article-title":"A\u00a0novel potent vasoconstrictor peptide produced by vascular endothelial cells","volume":"332","author":"Yanagisawa","year":"1988","journal-title":"Nature"},{"key":"10.1016\/j.ccm.2013.09.005_bib2","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1073\/pnas.86.8.2863","article-title":"The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes","volume":"86","author":"Inoue","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ccm.2013.09.005_bib3","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1165\/ajrcmb\/3.2.145","article-title":"Specific binding of endothelin on human bronchial smooth muscle cells in culture and secretion of endothelin-like material from bronchial epithelial cells","volume":"3","author":"Mattoli","year":"1990","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.ccm.2013.09.005_bib4","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/j.1476-5381.1995.tb13262.x","article-title":"Secretion of endothelin-1 and endothelin-3 by human cultured vascular smooth muscle cells","volume":"114","author":"Yu","year":"1995","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.ccm.2013.09.005_bib5","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1084\/jem.172.6.1741","article-title":"Endothelins, peptides with potent vasoactive properties, are produced by human macrophages","volume":"172","author":"Ehrenreich","year":"1990","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.ccm.2013.09.005_bib6","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1146\/annurev.physiol.61.1.391","article-title":"Pathophysiology of endothelin in the cardiovascular system","volume":"61","author":"Miyauchi","year":"1999","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.ccm.2013.09.005_bib7","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1164\/ajrccm.154.3.8810589","article-title":"Endothelins and the lung","volume":"154","author":"Michael","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ccm.2013.09.005_bib8","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1161\/01.STR.22.3.378","article-title":"Effect of carbon dioxide and oxygen on endothelin production by cultured porcine cerebral endothelial cells","volume":"22","author":"Yoshimoto","year":"1991","journal-title":"Stroke"},{"key":"10.1016\/j.ccm.2013.09.005_bib9","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1172\/JCI114488","article-title":"Endothelin receptor is coupled to phospholipase C via pertussis toxin insensitive guanine nucleotide binding regulatory protein in vascular smooth muscle cells","volume":"85","author":"Takuwa","year":"1990","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.ccm.2013.09.005_bib10","first-page":"E412","article-title":"Endothelin stimulates protein synthesis in smooth muscle cells","volume":"262","author":"Chua","year":"1992","journal-title":"Am J Physiol"},{"key":"10.1016\/j.ccm.2013.09.005_bib11","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1164\/ajrccm.165.3.2104059","article-title":"ETA and ETB receptors modulate the proliferation of human pulmonary artery smooth muscle cells","volume":"165","author":"Davie","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ccm.2013.09.005_bib12","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1172\/JCI116338","article-title":"Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells","volume":"91","author":"Hirata","year":"1993","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.ccm.2013.09.005_bib13","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1146\/annurev.pa.35.040195.001315","article-title":"Possible role of endothelin in endothelial regulation of vascular tone","volume":"35","author":"Masaki","year":"1995","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.ccm.2013.09.005_bib14","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1006\/pupt.2000.0242","article-title":"Importance of local production of endothelin-1 and of the ETB receptor in the regulation of pulmonary vascular tone","volume":"13","author":"Dupuis","year":"2000","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.ccm.2013.09.005_bib15","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1056\/NEJM199306173282402","article-title":"Expression of endothelin-1 in the lungs of patients with pulmonary hypertension","volume":"328","author":"Giaid","year":"1993","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl 9","key":"10.1016\/j.ccm.2013.09.005_bib16","first-page":"II-346","article-title":"Dynamic changes of endothelin-1, nitric oxide, and cyclic GMP in patients with congenital heart disease","volume":"96","author":"Bando","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.ccm.2013.09.005_bib17","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1034\/j.1399-3003.2000.15d04.x","article-title":"Endothelin mediates pulmonary vascular remodelling in a canine model of chronic embolic pulmonary hypertension","volume":"15","author":"Kim","year":"2000","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ccm.2013.09.005_bib18","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1161\/hc0902.105719","article-title":"Selective upregulation of endothelin B receptor gene expression in severe pulmonary hyper- tension","volume":"105","author":"Bauer","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ccm.2013.09.005_bib19","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jacc.2005.04.050","article-title":"Ambrisentan therapy for pulmonary arterial hypertension","volume":"46","author":"Gali\u00e9","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"23","key":"10.1016\/j.ccm.2013.09.005_bib20","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1161\/CIRCULATIONAHA.107.742510","article-title":"Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2","volume":"117","author":"Gali\u00e8","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.ccm.2013.09.005_bib21","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(01)06250-X","article-title":"Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo controlled study","volume":"358","author":"Channick","year":"2001","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.ccm.2013.09.005_bib22","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension","volume":"346","author":"Rubin","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccm.2013.09.005_bib23","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0140-6736(08)60919-8","article-title":"Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomized controlled trial","volume":"37","author":"Gali\u00e8","year":"2008","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ccm.2013.09.005_bib24","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1161\/CIRCULATIONAHA.106.630715","article-title":"Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study","volume":"114","author":"Gali\u00e8","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.ccm.2013.09.005_bib25","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1183\/09031936.05.00054804","article-title":"Survival with first-line bosentan in patients with primary pulmonary hypertension","volume":"25","author":"McLaughlin","year":"2005","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.ccm.2013.09.005_bib26","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ccm.2006.12.002","article-title":"The nitric oxide\/cGMP signaling pathway in pulmonary hypertension","volume":"28","author":"Klinger","year":"2007","journal-title":"Clin Chest Med"},{"issue":"3","key":"10.1016\/j.ccm.2013.09.005_bib27","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/00000542-199303000-00005","article-title":"Inhaled nitric oxide selectively reverses human hypoxic pulmonary vasoconstriction without causing systemic vasodilation","volume":"78","author":"Frostell","year":"1993","journal-title":"Anesthesiology"},{"issue":"1","key":"10.1016\/j.ccm.2013.09.005_bib28","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1476-5381.1995.tb14913.x","article-title":"Evidence that nitric oxide from the endothelium attenuates inherent tone in isolated pulmonary arteries from rats with hypoxic pulmonary hypertension","volume":"114","author":"Wanstall","year":"1995","journal-title":"Br J Pharmacol"},{"issue":"3 Pt 1","key":"10.1016\/j.ccm.2013.09.005_bib29","first-page":"L308","article-title":"Brain natriuretic peptide: possible role in the modulation of hypoxic pulmonary hypertension","volume":"266","author":"Hill","year":"1994","journal-title":"Am J Physiol"},{"issue":"1","key":"10.1016\/j.ccm.2013.09.005_bib30","doi-asserted-by":"crossref","first-page":"H58","DOI":"10.1152\/ajpheart.2002.282.1.H58","article-title":"Targeted disruption of the gene for natriuretic peptide receptor-A worsens hypoxia-induced cardiac hypertrophy","volume":"282","author":"Klinger","year":"2002","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"5","key":"10.1016\/j.ccm.2013.09.005_bib31","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1161\/01.CIR.99.5.605","article-title":"NPR-A-deficient mice show increased susceptibility to hypoxia-induced pulmonary hypertension","volume":"99","author":"Zhao","year":"1999","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.ccm.2013.09.005_bib32","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1016\/j.peptides.2006.05.023","article-title":"Renal hyporesponsiveness to brain natriuretic peptide: both generation and renal activity of cGMP are decreased in patients with pulmonary hypertension","volume":"27","author":"Charloux","year":"2006","journal-title":"Peptides"},{"issue":"12","key":"10.1016\/j.ccm.2013.09.005_bib33","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1136\/thx.52.12.1051","article-title":"Decreased nitric oxide in the exhaled air of patients with systemic sclerosis with pulmonary hypertension","volume":"52","author":"Kharitonov","year":"1997","journal-title":"Thorax"},{"key":"10.1016\/j.ccm.2013.09.005_bib34","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.201304-0686PP","article-title":"Nitric oxide deficiency and endothelial dysfunction in pulmonary arterial hypertension","author":"Klinger","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ccm.2013.09.005_bib35","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1152\/jappl.2001.91.3.1421","article-title":"Invited review: cGMP-dependent protein kinase signaling mechanisms in smooth muscle: from the regulation of tone to gene expression","volume":"91","author":"Lincoln","year":"2001","journal-title":"J\u00a0Appl Physiol"},{"issue":"5444","key":"10.1016\/j.ccm.2013.09.005_bib36","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1126\/science.286.5444.1583","article-title":"Regulation of myosin phosphatase by a specific interaction with cGMP-dependent protein kinase I alpha","volume":"286","author":"Surks","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.ccm.2013.09.005_bib37","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1046\/j.1432-1327.2000.01297.x","article-title":"Phosphorylation of phosphodiesterase-5 by cyclic nucleotide-dependent protein kinase alters its catalytic and allosteric cGMP-binding activities","volume":"267","author":"Corbin","year":"2000","journal-title":"Eur J Biochem"},{"issue":"3","key":"10.1016\/j.ccm.2013.09.005_bib38","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.pharmthera.2005.07.003","article-title":"Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents","volume":"109","author":"Lugnier","year":"2006","journal-title":"Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.ccm.2013.09.005_bib39","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.2174\/138161210790963760","article-title":"Cyclic nucleotide phosphodiesterases (PDE) and peptide motifs","volume":"16","author":"Keravis","year":"2010","journal-title":"Curr Pharm Des"},{"issue":"11","key":"10.1016\/j.ccm.2013.09.005_bib40","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1161\/CIRCRESAHA.107.162511","article-title":"Phosphodiesterase type 5: expanding roles in cardiovascular regulation","volume":"101","author":"Kass","year":"2007","journal-title":"Circ Res"},{"issue":"2","key":"10.1016\/j.ccm.2013.09.005_bib41","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0022-3565(24)37102-2","article-title":"Phosphodiesterase isoforms in the pulmonary arterial circulation of the rat: changes in pulmonary hypertension","volume":"283","author":"Maclean","year":"1997","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.ccm.2013.09.005_bib42","first-page":"L931","article-title":"Chronic pulmonary hypertension increases fetal lung cGMP phosphodiesterase activity","volume":"275","author":"Hanson","year":"1998","journal-title":"Am J Physiol"},{"key":"10.1016\/j.ccm.2013.09.005_bib43","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ehj.2004.01.013","article-title":"Clinical and haemodynamic effects of sildenafil in pulmonary hypertension: acute and mid-term effects","volume":"25","author":"Mikhail","year":"2004","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ccm.2013.09.005_bib44","doi-asserted-by":"crossref","first-page":"68S","DOI":"10.1016\/j.jacc.2004.02.031","article-title":"Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension","volume":"43","author":"Ghofrani","year":"2004","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"20","key":"10.1016\/j.ccm.2013.09.005_bib45","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1161\/01.CIR.0000016641.12984.DC","article-title":"Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide","volume":"105","author":"Michelakis","year":"2002","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.ccm.2013.09.005_bib46","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1097\/00000542-200006000-00030","article-title":"Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension","volume":"92","author":"Weimann","year":"2000","journal-title":"Anesthesiology"},{"issue":"4","key":"10.1016\/j.ccm.2013.09.005_bib47","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1161\/hc2901.093117","article-title":"Sildenafil inhibits hypoxia-induced pulmonary hypertension","volume":"104","author":"Zhao","year":"2001","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.ccm.2013.09.005_bib48","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1164\/rccm.200406-804OC","article-title":"Sildenafil inhibits altitude-induced hypoxemia and pulmonary hypertension","volume":"171","author":"Richalet","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"issue":"S1","key":"10.1016\/j.ccm.2013.09.005_bib49","first-page":"A295","article-title":"IC351 enhances nitric oxide-mediated relaxation of human arterial and trabecular penile smooth muscle","volume":"44","author":"Angulo","year":"2001","journal-title":"Diabetologia"},{"key":"10.1016\/j.ccm.2013.09.005_bib50","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1378\/chest.120.3.866","article-title":"Vasoresponsiveness of sarcoidosis-associated pulmonary hypertension","volume":"120","author":"Preston","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.ccm.2013.09.005_bib51","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1164\/ajrccm.164.9.2105060","article-title":"Coaerosolization of phosphodiesterase inhibitors markedly enhances the pulmonary vasodilatory response to inhaled iloprost in experimental pulmonary hypertension. Maintenance of lung selectivity","volume":"164","author":"Schermuly","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ccm.2013.09.005_bib52","doi-asserted-by":"crossref","first-page":"L1361","DOI":"10.1152\/ajplung.2001.281.6.L1361","article-title":"Combination of nonspecific PDE inhibitors with inhaled prostacyclin in experimental pulmonary hypertension","volume":"281","author":"Schermuly","year":"2001","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.ccm.2013.09.005_bib53","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1097\/00003246-200105000-00024","article-title":"Nebulized sildenafil is a selective pulmonary vasodilator in lambs with acute pulmonary hypertension","volume":"29","author":"Ichinose","year":"2001","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ccm.2013.09.005_bib54","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1177\/153537020422900908","article-title":"Synergistic effects of ANP and sildenafil on cGMP levels and amelioration of acute hypoxic pulmonary hypertension","volume":"229","author":"Preston","year":"2004","journal-title":"Exp Biol Med (Maywood)"},{"key":"10.1016\/j.ccm.2013.09.005_bib55","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1161\/01.CIR.0000074226.20466.B1","article-title":"Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension","volume":"107","author":"Sebkhi","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ccm.2013.09.005_bib56","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1164\/rccm.200302-282OC","article-title":"Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats","volume":"169","author":"Schermuly","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ccm.2013.09.005_bib57","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1161\/01.CIR.0000050653.10758.6B","article-title":"Beneficial effects of phosphodiesterase 5 inhibition in pulmonary hypertension are influenced by natriuretic peptide activity","volume":"107","author":"Zhao","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ccm.2013.09.005_bib58","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1378\/chest.125.2.580","article-title":"Hemodynamic response to sildenafil, nitric oxide, and iloprost in primary pulmonary hypertension","volume":"125","author":"Leuchte","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.ccm.2013.09.005_bib59","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/j.rmed.2005.03.026","article-title":"Acute and chronic effects of sildenafil in patients with pulmonary arterial hypertension","volume":"99","author":"Preston","year":"2005","journal-title":"Respir Med"},{"key":"10.1016\/j.ccm.2013.09.005_bib60","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1161\/hc3601.096826","article-title":"Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension","volume":"104","author":"Wilkens","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.ccm.2013.09.005_bib61","first-page":"55","article-title":"The efficacy and tolerability of sildenafil in patients with moderate-to-severe pulmonary hypertension","volume":"55","author":"Bharani","year":"2003","journal-title":"Indian Heart J"},{"key":"10.1016\/j.ccm.2013.09.005_bib62","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.jacc.2003.10.056","article-title":"Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study","volume":"43","author":"Sastry","year":"2004","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ccm.2013.09.005_bib63","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMoa050010","article-title":"Sildenafil citrate therapy for pulmonary arterial hypertension","volume":"353","author":"Galie","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccm.2013.09.005_bib64","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1089\/ham.2005.6.43","article-title":"Effects of sildenafil on the human response to acute hypoxia and exercise","volume":"6","author":"Ricart","year":"2005","journal-title":"High Alt Med Biol"},{"key":"10.1016\/j.ccm.2013.09.005_bib65","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1136\/thx.2005.041954","article-title":"Phosphodiesterase type 5 and high altitude pulmonary hypertension","volume":"60","author":"Aldashev","year":"2005","journal-title":"Thorax"},{"key":"10.1016\/j.ccm.2013.09.005_bib66","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1164\/rccm.200210-1157BC","article-title":"Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension","volume":"167","author":"Ghofrani","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ccm.2013.09.005_bib67","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(02)11024-5","article-title":"Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial","volume":"360","author":"Ghofrani","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ccm.2013.09.005_bib68","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1378\/chest.127.5.1647","article-title":"Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: combined administration with inhaled nitric oxide","volume":"127","author":"Lepore","year":"2005","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.ccm.2013.09.005_bib69","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.eururo.2004.04.026","article-title":"Efficacy and treatment satisfaction with on-demand tadalafil (Cialis) in men with erectile dysfunction","volume":"46","author":"Skoumal","year":"2004","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.ccm.2013.09.005_bib70","first-page":"901","article-title":"Prospective, randomized, open-label, fixed-dose, crossover study to establish preference of patients with erectile dysfunction after taking the three PDE-5 inhibitors","volume":"3","author":"Tolr\u00e0","year":"2006","journal-title":"J\u00a0Sex Med"},{"issue":"7","key":"10.1016\/j.ccm.2013.09.005_bib71","first-page":"1488","article-title":"Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study","volume":"44","author":"Ghofrani","year":"2004","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.ccm.2013.09.005_bib72","doi-asserted-by":"crossref","first-page":"743","DOI":"10.7326\/0003-4819-141-9-200411020-00033","article-title":"Tadalafil in primary pulmonary arterial hypertension","volume":"141","author":"Palmieri","year":"2004","journal-title":"Ann Intern Med"},{"issue":"17","key":"10.1016\/j.ccm.2013.09.005_bib73","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1161\/CIRCULATIONAHA.105.603001","article-title":"Phosphodiesterase-5 inhibitor in Eisenmenger syndrome: a preliminary observational study","volume":"114","author":"Mukhopadhyay","year":"2006","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.ccm.2013.09.005_bib74","first-page":"329","article-title":"Oral tadalafil in pulmonary artery hypertension: a prospective study","volume":"59","author":"Aggarwal","year":"2007","journal-title":"Indian Heart J"},{"issue":"4","key":"10.1016\/j.ccm.2013.09.005_bib75","first-page":"323","article-title":"Efficacy and safety of PDE-5 inhibitor tadalafil in pulmonary arterial hypertension","volume":"59","author":"Bharani","year":"2007","journal-title":"Indian Heart J"},{"key":"10.1016\/j.ccm.2013.09.005_bib76","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1161\/CIRCULATIONAHA.108.839274","article-title":"Tadalafil therapy for pulmonary arterial hypertension","volume":"11","author":"Galie","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ccm.2013.09.005_bib77","doi-asserted-by":"crossref","first-page":"367A","DOI":"10.1378\/chest.10870","article-title":"Tadalafil in geriatric patients with pulmonary arterial hypertension","volume":"138","author":"Arneson","year":"2010","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.ccm.2013.09.005_bib78","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1007\/s11096-008-9229-0","article-title":"Pulmonary embolism after tadalafil ingestion","volume":"30","author":"Chen","year":"2008","journal-title":"Pharm World Sci"},{"issue":"8","key":"10.1016\/j.ccm.2013.09.005_bib79","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1136\/bjo.84.8.928g","article-title":"Branch retinal artery occlusion; another complication of sildenafil","volume":"84","author":"Tripathi","year":"2000","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"10.1016\/j.ccm.2013.09.005_bib80","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1089\/jop.2005.21.315","article-title":"Case report: association of combined nonarteritic anterior ischemic optic neuropathy (NAION) and obstruction of cilioretinal artery with overdose of Viagra","volume":"21","author":"Akash","year":"2005","journal-title":"J\u00a0Ocul Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.ccm.2013.09.005_bib81","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/sj.eye.6701614","article-title":"Tadalafil-associated anterior ischaemic optic neuropathy","volume":"19","author":"Peter","year":"2005","journal-title":"Eye (Lond)"},{"issue":"3","key":"10.1016\/j.ccm.2013.09.005_bib82","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1001\/archopht.123.3.400","article-title":"Recurrent visual field defect and ischemic optic neuropathy associated with tadalafil rechallenge","volume":"123","author":"Bollinger","year":"2005","journal-title":"Arch Ophthalmol"},{"issue":"11","key":"10.1016\/j.ccm.2013.09.005_bib83","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1164\/rccm.200410-1411OC","article-title":"Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study","volume":"171","author":"Wilkins","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.ccm.2013.09.005_bib84","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/1753465812463627","article-title":"Tadalafil as monotherapy and in combination regimens for the treatment of pulmonary arterial hypertension","volume":"7","author":"Udeoji","year":"2013","journal-title":"Ther Adv Respir Dis"},{"issue":"8","key":"10.1016\/j.ccm.2013.09.005_bib85","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.jacc.2012.05.004","article-title":"Tadalafil for the treatment of pulmonary arterial hypertension: a double-blind 52-week uncontrolled extension study","volume":"60","author":"Oudiz","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"}],"container-title":["Clinics in Chest Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272523113001354?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272523113001354?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:49:45Z","timestamp":1759452585000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272523113001354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":85,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S0272523113001354"],"URL":"https:\/\/doi.org\/10.1016\/j.ccm.2013.09.005","relation":{},"ISSN":["0272-5231"],"issn-type":[{"type":"print","value":"0272-5231"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral Therapies for Pulmonary Arterial Hypertension","name":"articletitle","label":"Article Title"},{"value":"Clinics in Chest Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccm.2013.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}